首页> 外文OA文献 >Targeting the Sonic Hedgehog Pathway to Suppress the Expression of the Cancer Stem Cell (CSC)—Related Transcription Factors and CSC-Driven Thyroid Tumor Growth
【2h】

Targeting the Sonic Hedgehog Pathway to Suppress the Expression of the Cancer Stem Cell (CSC)—Related Transcription Factors and CSC-Driven Thyroid Tumor Growth

机译:靶向Sonic Hedgehog途径以抑制癌症干细胞(CSC)相关的转录因子和CSC驱动的甲状腺肿瘤生长的表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The sonic hedgehog (Shh) pathway plays important roles in tumorigenesis, tumor growth, drug resistance, and metastasis. We and others have reported earlier that this pathway is highly activated in thyroid cancer. However, its role in thyroid cancer stem cell (CSC) self-renewal and tumor development remains incompletely understood. B lymphoma Mo-MLV insertion region 1 homolog (BMI1) and SRY-Box Transcription Factor 2 (SOX2) are two CSC-related transcription factors that have been implicated in promoting CSC self-renewal. The objective of our current investigation was to determine the role of the Shh pathway in regulating BMI1 and SOX2 expression in thyroid cancer and promoting thyroid tumor growth and development. Here we report that inhibition of the Shh pathway by Gli1 siRNA or by cyclopamine and GANT61 reduced BMI1 and SOX2 expression in SW1736 and KAT-18 cells, two anaplastic thyroid cancer cell lines. The opposite results were obtained in cells overexpressing Gli1 or its downstream transcription factor Snail. The Shh pathway regulated SOX2 and BMI1 expression at a transcriptional and post-transcriptional level, respectively. GANT61 treatment suppressed the growth of SW1736 CSC-derived tumor xenografts but did not significantly inhibit the growth of tumors grown from bulk tumor cells. Clinicopathological analyses of thyroid tumor specimens by immunohistochemical (IHC) staining revealed that BMI1 and SOX2 were highly expressed in thyroid cancer and correlated with Gli1 expression. Our study provides evidence that activation of the Shh pathway leads to increased BMI1 and SOX2 expression in thyroid cancer and promotes thyroid CSC-driven tumor initiation. Targeting the Shh pathway may have therapeutic value for treating thyroid cancer and preventing recurrence.
机译:Sonic Hedgehog(SHH)途径在肿瘤发生,肿瘤生长,耐药性和转移中起重要作用。我们和其他人早些人报告说,这种途径在甲状腺癌中高度激活。然而,其在甲状腺癌干细胞(CSC)的自我更新和肿瘤发育中的作用仍然不完全理解。 B淋巴瘤MO-MLV插入区域1同源物(BMI1)和Sry-Box转录因子2(Sox2)是两种与CSC相关的转录因子,其涉及促进CSC自我更新。我们目前调查的目的是确定SHH途径在调节甲状腺癌中的BMI1和SOX2表达中的作用,促进甲状腺肿瘤生长和发育。在这里,我们报告称SHH1 siRNA或Cyclopamine和Gant61在SW1736和Kat-18细胞中减少了BMI1和SOX2表达的SHH途径,两种动产剂甲状腺癌细胞系。在过表达GLI1或其下游转录因子蜗牛的细胞中获得相反的结果。 SHH途径分别调节SOX2和BMI1在转录后和转录后水平的表达。 Gant61治疗抑制了SW1736 CSC衍生的肿瘤异种移植物的生长,但没有显着抑制从散装肿瘤细胞生长的肿瘤的生长。通过免疫组织化学(IHC)甲状腺肿瘤标本的临床病理分析染色显示BMI1和SOX2在甲状腺癌中高表达,并与表达中Gli1相关。我们的研究提供了证据表明,SHH途径的激活导致甲状腺癌中的BMI1和SOx2表达增加,并促进甲状腺CSC驱动的肿瘤引发。靶向SHH途径可能具有治疗甲状腺癌并预防复发的治疗价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号